Skip to main content

Advertisement

SpringerLink
Log in

Pegaptanib sodium

  • Fresh from the Pipeline
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

Abstract

In December 2004, pegaptanib sodium (Macugen; Eyetech/Pfizer), which targets vascular endothelial growth factor, was approved by the US FDA for the treatment of neovascular age-related macular degeneration. As well as being the first anti-angiogenic agent to be approved for this common eye disorder, it is also the first approved therapeutic based on an RNA structure known as an aptamer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Neovascular age-related macular degeneration and pegaptanib.

References

  1. Congdon, N. et al. Causes and prevalence of visual impairment among adults in the United States. Arch. Ophthalmol. 122, 477–485 (2004).

    Article  Google Scholar 

  2. Fine, S. L. et al. Age-related macular degeneration. N. Engl. J. Med. 342, 483–492 (2000).

    Article  CAS  Google Scholar 

  3. Clark, A. F. & Yorio, T. Ophthalmic drug discovery. Nature Rev. Drug Discov. 2, 448–459 (2003).

    Article  CAS  Google Scholar 

  4. Ferrara, N., Gerber, H. P. & LeCouter, J. The biology of VEGF and its receptors. Nature Med. 9, 669–676 (2003).

    Article  CAS  Google Scholar 

  5. Aiello, L. P. et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331, 1480–1487 (1994).

    Article  CAS  Google Scholar 

  6. Ruckman, J. et al. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 273, 20556–20567 (1998).

    Article  CAS  Google Scholar 

  7. FDA labelling information [online], <http://www.fda.gov/cder/foi/label/2004/021756lbl.pdf> (2004).

  8. Gragoudas, E. S. et al. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351, 2805–2816 (2004).

    Article  CAS  Google Scholar 

  9. Age-Related Eye Diseases Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta-carotene, and zinc for age-related macular degeneration and vision loss. AREDS report no. 8. Arch. Ophthalmol. 119, 1417–1436 (2001).

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania Health System, 51 North 39th Street, Philadelphia, 19104-2689, Pennsylvania, USA

    Stuart L. Fine

  2. Department of Ophthalmology, Emory University School of Medicine, 1365B Clifton Road, Atlanta, 30322, Georgia, USA

    Daniel F. Martin

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery,

    Peter Kirkpatrick

Authors
  1. Stuart L. Fine
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel F. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Stuart L. Fine or Peter Kirkpatrick.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fine, S., Martin, D. & Kirkpatrick, P. Pegaptanib sodium. Nat Rev Drug Discov 4, 187–188 (2005). https://doi.org/10.1038/nrd1677

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1677

  • Springer Nature Limited

This article is cited by

Search

Navigation